ImmuCell Corp
NASDAQ:ICCC
ImmuCell Corp
Revenue
ImmuCell Corp
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ImmuCell Corp
NASDAQ:ICCC
|
Revenue
$17.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is ImmuCell Corp's Revenue?
Revenue
17.5m
USD
Based on the financial report for Dec 31, 2023, ImmuCell Corp's Revenue amounts to 17.5m USD.
What is ImmuCell Corp's Revenue growth rate?
Revenue CAGR 10Y
11%
Over the last year, the Revenue growth was -6%. The average annual Revenue growth rates for ImmuCell Corp have been 4% over the past three years , 10% over the past five years , and 11% over the past ten years .